Mechanistically, we demonstrate that NRF2 binds to the Gsdmd promoter at the −2110 ‐ 1130 bp site, inhibiting the GSDMD expression and thereby improving glucose/lipid metabolism and liver steatosis. This evidence concerns the gene GSDMD and fatty liver disease.